Compare VIPS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIPS | CYTK |
|---|---|---|
| Founded | 2008 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 8.0B |
| IPO Year | 2012 | 2004 |
| Metric | VIPS | CYTK |
|---|---|---|
| Price | $20.19 | $60.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $19.83 | ★ $77.87 |
| AVG Volume (30 Days) | ★ 2.8M | 1.8M |
| Earning Date | 11-20-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.94 | N/A |
| Revenue | ★ $14,983,370,343.00 | $87,211,000.00 |
| Revenue This Year | $1.00 | $361.33 |
| Revenue Next Year | $2.40 | $65.14 |
| P/E Ratio | $10.40 | ★ N/A |
| Revenue Growth | N/A | ★ 2609.26 |
| 52 Week Low | $12.14 | $29.31 |
| 52 Week High | $21.08 | $69.33 |
| Indicator | VIPS | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 59.72 | 41.98 |
| Support Level | $19.50 | $63.50 |
| Resistance Level | $20.49 | $67.26 |
| Average True Range (ATR) | 0.65 | 2.79 |
| MACD | 0.05 | -0.89 |
| Stochastic Oscillator | 88.77 | 4.57 |
Vipshop is a leading Chinese online discount retailer offering branded products at attractive discounts ranging from 10%-90% off their original price through daily flash sales. It operates warehousing, retailing, product procurements, software development, and information technology support in-house while outsourcing to third-party logistics providers for distribution and shipments. Branded products on Vipshop's platform are sourced mostly through a consignment model with global brand partners . As of March 31, 2025, Eric Ya Shen, chairman and CEO, had 64.5% voting rights. Leading Chinese social media firm and strategic shareholder Tencent also holds an 12.5% interest.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.